FGFR4 Prevents Hyperlipidemia and Insulin Resistance but Underlies High-Fat Diet–Induced Fatty Liver
FGFR4 Prevents Hyperlipidemia and Insulin Resistance but Underlies High-Fat Diet–Induced Fatty Liver Xinqiang Huang , Chaofeng Yang , Yongde Luo , Chengliu Jin , Fen Wang and Wallace L. McKeehan From the Center for Cancer and Stem Cell Biology, Institute of Biosciences and Technology, Texas A&M...
Gespeichert in:
Veröffentlicht in: | Diabetes (New York, N.Y.) N.Y.), 2007-10, Vol.56 (10), p.2501-2510 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | FGFR4 Prevents Hyperlipidemia and Insulin Resistance but Underlies High-Fat Diet–Induced Fatty Liver
Xinqiang Huang ,
Chaofeng Yang ,
Yongde Luo ,
Chengliu Jin ,
Fen Wang and
Wallace L. McKeehan
From the Center for Cancer and Stem Cell Biology, Institute of Biosciences and Technology, Texas A&M Health Science Center,
Houston, Texas
Address correspondence and reprint requests to Wallace L. McKeehan, PhD, Center for Cancer and Stem Cell Biology, Institute
of Biosciences and Technology, Texas A&M Health Science Center, 2121 W. Holcombe Blvd., Houston, TX 77030. E-mail: wmckeehan{at}ibt.tamhsc.edu
Abstract
OBJECTIVE— Fibroblast growth factor (FGF) family signaling largely controls cellular homeostasis through short-range intercell paracrine
communication. Recently FGF15/19, 21, and 23 have been implicated in endocrine control of metabolic homeostasis. The identity
and location of the FGF receptor isotypes that mediate these effects are unclear. The objective was to determine the role
of FGFR4, an isotype that has been proposed to mediate an ileal FGF15/19 to hepatocyte FGFR4 axis in cholesterol homeostasis,
in metabolic homeostasis in vivo.
RESEARCH DESIGN AND METHODS— FGFR4 −/− mice—mice overexpressing constitutively active hepatic FGFR4—and FGFR4 −/− with constitutively active hepatic FGFR4 restored in the liver were subjected to a normal and a chronic high-fat diet sufficient
to result in obesity. Systemic and liver-specific metabolic phenotypes were then characterized.
RESULTS— FGFR4-deficient mice on a normal diet exhibited features of metabolic syndrome that include increased mass of white adipose
tissue, hyperlipidemia, glucose intolerance, and insulin resistance, in addition to hypercholesterolemia. Surprisingly, the
FGFR4 deficiency alleviated high-fat diet–induced fatty liver in obese mice, which is also a correlate of metabolic syndrome.
Restoration of FGFR4, specifically in hepatocytes of FGFR4-deficient mice, decreased plasma lipid levels and restored the
high-fat diet–induced fatty liver but failed to restore glucose tolerance and sensitivity to insulin.
CONCLUSIONS— FGFR4 plays essential roles in systemic lipid and glucose homeostasis. FGFR4 activity in hepatocytes that normally serves
to prevent systemic hyperlipidemia paradoxically underlies the fatty liver disease associated with chronic high-fat intake
and obesity.
FGF, fibroblast growth factor
FXR, farnesoid X receptor
G6Pase, glucose-6-phosphatase
NAFLD, nonalcoholic fatty liver disease
PP |
---|---|
ISSN: | 0012-1797 1939-327X |
DOI: | 10.2337/db07-0648 |